Drug-drug interactions between antiemetics used in cancer patients

Umar, Rashida Muhammad

doi:10.1016/j.jons.2018.07.003

Cited by 15 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Respecto de los esquemas terapéuticos empleados, se evidenció en toda la literatura consultada que estos guardaban un alto grado de similaridad; por otra parte, se incluyeron solo medicamentos disponibles en el país. Por ello, en función del riesgo de desarrollar NyV se describen a continuación los siguientes esquemas (13,28,29):…”

Section: Esquemas Para La Prevención Y Manejo De Náuseas Y Vómito Asociado a Quimioterapiaunclassified

“…Pueden afectar entre el 8 % y el 14 % de los pacientes según el número de ciclo de quimioterapia evaluado. Los factores de riesgo más relevantes para el desarrollo de este tipo de náuseas son la aparición de NyV en el ciclo anterior y la presencia de ansiedad (28).…”

Section: Náuseas Y Vómitos Anticipatoriosunclassified

“…En caso de no lograr el control de los síntomas con el agregado de olanzapina o si el paciente ya presentaba un esquema con cuatro drogas, se puede rotar el antagonista de receptores de serotonina y el de neurocinina. Una buena opción es la combinación de 0,5 mg de palonosetrón con 300 mg de netupitant, aunque existe escasa evidencia de que esta rotación presente mayor efectividad (28)(29)(30).…”

Section: Náuseas Y Vómitos Refractariosunclassified

See 2 more Smart Citations

Manejo de náuseas y vómitos inducidos por quimioterapia en pacientes hematológicos

et al. 2021

View full text Add to dashboard Cite

Las náuseas y vómitos (NyV) constituyen dos de los efectos adversos frecuentemente asociados a la administración de quimioterapia además de otros fármacos empleados en hematología. La importancia que la prevención y el manejo de estos síntomas tiene en nuestros pacientes, radica en los riesgos que representan cuando no son tratados correctamente como por ejemplo: deshidratación, alteraciones hidroelectrolíticas e insuficiencia renal aguda. Para la elaboración este artículo se realizó una revisión de la literatura en función de la evidencia y esquemas disponibles para la prevención y tratamiento de NV inducido por medicamentos usados en el manejo de pacientes con patologías hematológicas.

show abstract

Section: Esquemas Para La Prevención Y Manejo De Náuseas Y Vómito Asociado a Quimioterapiaunclassified

Section: Náuseas Y Vómitos Anticipatoriosunclassified

Section: Náuseas Y Vómitos Refractariosunclassified

See 1 more Smart Citation

Manejo de náuseas y vómitos inducidos por quimioterapia en pacientes hematológicos

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The first-generation serotonin receptor antagonists ondansetron, granisetron, and dolasetron are known to produce electrocardiogram changes. 69 The majority of these changes are without clinical significance, however torsade de pointes has been associated with the QT interval prolongation they induce. The FDA recommends ECG monitoring for patients taking these agents at the same time as other QT prolonging medications.…”

Section: Qt Interval Prolongationmentioning

confidence: 99%

Hypertension and QT interval prolongation associated with targeted systemic cancer therapies

Fahey

Piccolo

Bergsbaken

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective To summarize the proposed mechanisms behind hypertension and QT interval prolongation associated with use of targeted systemic cancer therapies and provide recommendations for monitoring or managing these toxicities. Summary The cardiotoxic effects of targeted systemic cancer therapies represents a new paradigm of cancer treatment associated cardiovascular adverse events. National guidelines regarding optimal monitoring and management strategies for hypertension and QT interval prolongation associated with use of these therapies are lacking. While the pathophysiological drivers of hypertension due to targeted systemic cancer therapies differ by class of targeted therapy, general management strategies do not. Routine blood pressure monitoring throughout the duration of therapy is recommended for all agents. Patients who experience hypertension often can be treated with the addition or modification of antihypertensive therapies. Uncontrolled hypertension despite optimal medical management may require dose modifications or discontinuation of the targeted systemic cancer therapy. Electrocardiogram monitoring is recommended for patients who receive targeted therapies that may prolong the QT interval. Minimizing or managing drug interactions with other QT prolonging medications is recommended in addition to ensuring adequate electrolyte supplementation. Dose modifications or discontinuation of the targeted systemic therapy may be necessary for patients who experience QT interval prolongation. Conclusions Appropriate cardiovascular monitoring and timely management of treatment-emergent toxicities can optimize therapy for patients receiving targeted systemic cancer therapies associated with a risk of drug-induced hypertension or QT interval prolongation.

show abstract

“…An antiemetic is a drug that can relieve preventatively or curative vomiting and nausea (Li et al, 2016), metoclopramide is the most commonly used antiemetic medication and is administered orally (Umar, 2018).…”

Section: Introductionmentioning

confidence: 99%

The Development of New Molecules Having Antiemetic Activity Using Molecular Modeling

Kanouni¹,

Benguerba²

2019

Current Research in Bioinformatics

View full text Add to dashboard Cite

The solubility of a drug in water or in the blood represents the most desired parameter in medicine. Our aim is to obtain molecules with properties more effective than those of metoclopramide. In this work, two molecules with high solubility are constructed. Metoclopramide (a benzamide derivative) is a dopamine receptor antagonist used as an antiemetic drug. Its solubility in water is 200 mg/L at 25°C. In this work, we will develop two other molecules that have the same therapeutic activity of metoclopramide with a higher solubility in water, therefore in the blood, without affecting the other properties. The two molecules developed by molecular modeling with a chemical modification of the OH group of metoclopramide have a high solubility: approximately 3 times and 8 times that of metoclopramide. For the other physicochemical properties, there is a great similarity between the molecules. Thus, the two proposed molecules will have antiemetic activity, the second molecule will be more favorable because of its higher solubility and the number of HBA and HBD.

show abstract

Drug-drug interactions between antiemetics used in cancer patients

Cited by 15 publications

References 19 publications

Manejo de náuseas y vómitos inducidos por quimioterapia en pacientes hematológicos

Manejo de náuseas y vómitos inducidos por quimioterapia en pacientes hematológicos

Hypertension and QT interval prolongation associated with targeted systemic cancer therapies

The Development of New Molecules Having Antiemetic Activity Using Molecular Modeling

Contact Info

Product

Resources

About